Becton, Dickinson and Co. | BDX - Operating Expenses


Becton, Dickinson and Co. reported $4.16B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Agilent USD 1.43B 2M Jun/2026
Align Technology USD 821.72M 43.15M Sep/2026
AngioDynamics USD 81.95M 1.68M Sep/2025
Baxter International USD 6.5B 3.82B Sep/2026
Becton, Dickinson and Co. USD 4.16B 20.25B Sep/2026
Bio-Rad Laboratories USD 7.6B 429.1M Sep/2026
Boston Scientific USD 4.13B 72M Sep/2026
Cooper Companies USD 844.2M 268.3M Jun/2026
Danaher USD 53.62B 1.04B Sep/2026
Dentsply International USD 1.36B 4M Sep/2026
Dexcom USD 990.1M 53.5M Jun/2026
Edwards Lifesciences USD 10.86B 9.64B Sep/2026
Globus Medical USD 585.49M 250.09M Sep/2026
Insulet USD 652.2M 19.8M Sep/2026
Integra LifeSciences USD 368.53M 674.84M Sep/2026
Intuitive Surgical USD 2B 86.5M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Medtronic USD 7.92B 203M Jun/2026
Solventum Corp USD 4.81B 5M Sep/2026
Stryker USD 4.8B 118M Jun/2026
Tandem Diabetes Care USD 286.06M 17.71M Sep/2026
Teleflex USD 3.49B 589.18M Sep/2026
Terumo JPY 331.37B 109.04B Sep/2026
Thermo Fisher Scientific USD 9.68B 134M Sep/2026
Zimmer Biomet Holdings USD 1.72B 110.9M Sep/2026